In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pharming repurchases royalty rights from Paul Royalty

Executive Summary

Pharming Group NV has given Paul Royalty Fund royalty rights to recombinant human C1 inhibitor (rhC1INH), a therapeutic candidate in Phase III for hereditary angioedema.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Financing
    • Royalty Sale

Related Companies

Advertisement
UsernamePublicRestriction

Register